View Item 

Show simple item record

Progress in hepatitis B: A 30‐year journey through three continents
dc.contributor.authorLok, Anna Suk‐fongen_US
dc.date.accessioned2014-07-03T14:41:30Z
dc.date.availableWITHHELD_13_MONTHSen_US
dc.date.available2014-07-03T14:41:30Z
dc.date.issued2014-07en_US
dc.identifier.citationLok, Anna Suk‐fong (2014). "Progress in hepatitis B: A 30â year journey through three continents." Hepatology 60(1): 4-11.en_US
dc.identifier.issn0270-9139en_US
dc.identifier.issn1527-3350en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/107540
dc.publisherWiley Periodicals, Inc.en_US
dc.titleProgress in hepatitis B: A 30‐year journey through three continentsen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelInternal Medicine and Specialtiesen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/107540/1/hep27120.pdf
dc.identifier.doi10.1002/hep.27120en_US
dc.identifier.sourceHepatologyen_US
dc.identifier.citedreferenceLai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, et al. A one‐year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339: 61 ‐ 68.en_US
dc.identifier.citedreferenceCarman WF, Jacyna MR, Hadziyannis S, Karayiannis P, McGarvey MJ, Makris A, et al. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989; 2: 588 ‐ 591.en_US
dc.identifier.citedreferenceJunker‐Niepmann M, Bartenschlager R, Schaller H. A short cis‐acting sequence is required for hepatitis B virus pregenome encapsidation and sufficient for packaging of foreign RNA. EMBO J 1990; 9: 3389 ‐ 3396.en_US
dc.identifier.citedreferenceLok AS, Akarca U, Greene S. Mutations in the pre‐core region of hepatitis B virus serve to enhance the stability of the secondary structure of the pre‐genome encapsidation signal. Proc Natl Acad Sci U S A 1994; 91: 4077 ‐ 4081.en_US
dc.identifier.citedreferenceTong SP, Li JS, Vitvitski L, Kay A, Treepo C. Evidence for a base‐paired region of hepatitis B virus pregenome encapsidation signal which influences the patterns of precore mutations abolishing HBe protein expression. J Virol 1993; 67: 5651 ‐ 5655.en_US
dc.identifier.citedreferenceMcKenzie R, Fried MW, Sallie R, Conjeevaram H, Di Bisceglie AM, Park Y, et al. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med 1995; 333: 1099 ‐ 1105.en_US
dc.identifier.citedreferenceDienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341: 1256 ‐ 1263.en_US
dc.identifier.citedreferenceMarcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5‐year open‐label follow‐up study. Lancet 2013; 381: 468 ‐ 475.en_US
dc.identifier.citedreferenceLiaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521 ‐ 1531.en_US
dc.identifier.citedreferenceKim WR, Terrault NA, Pedersen RA, Therneau TM, Edwards E, Hindman AA, et al. Trends in waiting list registration for liver transplantation for viral hepatitis in the United States. Gastroenterology 2009; 137: 1680 ‐ 1686.en_US
dc.identifier.citedreferenceSamuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329: 1842 ‐ 1847.en_US
dc.identifier.citedreferenceDegertekin B, Han SH, Keeffe EB, Schiff ER, Luketic VA, Brown RS Jr, et al. Impact of virologic breakthrough and HBIG regimen on hepatitis B recurrence after liver transplantation. Am J Transplant 2010; 10: 1823 ‐ 1833.en_US
dc.identifier.citedreferenceChu CJ, Keeffe EB, Han SH, Perrillo RP, Min AD, Soldevila‐Pico C, et al. Hepatitis B virus genotypes in the United States: results of a nationwide study. Gastroenterology 2003; 125: 444 ‐ 451.en_US
dc.identifier.citedreferenceKowdley KV, Wang CC, Welch S, Roberts H, Brosgart CL. Prevalence of chronic hepatitis B among foreign‐born persons living in the United States by country of origin. Hepatology 2012; 56: 422 ‐ 433.en_US
dc.identifier.citedreferenceLam KC, Lai CL, Trepo C, Wu PC. Deleterious effect of prednisolone in HBsAg‐positive chronic active hepatitis. N Engl J Med 1981; 304: 380 ‐ 386.en_US
dc.identifier.citedreferenceGreenberg HB, Pollard RB, Lutwick LI, Gregory PB, Robinson WS, Merigan TC. Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis. N Engl J Med 1976; 295: 517 ‐ 522.en_US
dc.identifier.citedreferenceLok AS, Weller IV, Karayiannis P, Brown D, Fowler MJ, Monjardino J, et al. Thrice weekly lymphoblastoid interferon is effective in inhibiting hepatitis B virus replication. Liver 1984; 4: 45 ‐ 49.en_US
dc.identifier.citedreferenceSmith CI, Kitchen LW, Scullard GH, Robinson WS, Gregory PB, Merigan TC. Vidarabine monophosphate and human leukocyte interferon in chronic hepatitis B infection. JAMA 1982; 247: 2261 ‐ 2265.en_US
dc.identifier.citedreferenceHoofnagle JH, Minuk GY, Dusheiko GM, Schafer DF, Johnson R, Straus S, et al. Adenine arabinoside 5'‐monophosphate treatment of chronic type B hepatitis. Hepatology 1982; 2: 784 ‐ 788.en_US
dc.identifier.citedreferenceLok AS, Novick DM, Karayiannis P, Dunk AA, Sherlock S, Thomas HC. A randomized study of the effects of adenine arabinoside 5'‐monophosphate (short or long courses) and lymphoblastoid interferon on hepatitis B virus replication. Hepatology 1985; 5: 1132 ‐ 1138.en_US
dc.identifier.citedreferenceLok AS, Hadziyannis SJ, Weller IV, Karvountzis MG, Monjardino J, Karayiannis P, et al. Contribution of low level HBV replication to continuing inflammatory activity in patients with anti‐HBe positive chronic hepatitis B virus infection. Gut 1984; 25: 1283 ‐ 1287.en_US
dc.identifier.citedreferenceLai CL, Lok AS, Lin HJ, Wu PC, Yeoh EK, Yeung CY. Placebo‐controlled trial of recombinant alpha 2‐interferon in Chinese HBsAg‐carrier children. Lancet 1987; 2: 877 ‐ 880.en_US
dc.identifier.citedreferenceLok AS, Lai CL, Wu PC, Leung EK. Long‐term follow‐up in a randomised controlled trial of recombinant alpha 2‐interferon in Chinese patients with chronic hepatitis B infection. Lancet 1988; 2: 298 ‐ 302.en_US
dc.identifier.citedreferenceLok AS, Wu PC, Lai CL, Lau JY, Leung EK, Wong LS, et al. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology 1992; 102: 2091 ‐ 2097.en_US
dc.identifier.citedreferencePerrillo RP, Schiff ER, Davis GL, Bodenheimer HC Jr, Lindsay K, Payne J, et al. A randomized, controlled trial of interferon alfa‐2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N Engl J Med 1990; 323: 295 ‐ 301.en_US
dc.identifier.citedreferenceLok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991; 100: 182 ‐ 188.en_US
dc.identifier.citedreferenceHwang JP, Lok AS. Management of patients with hepatitis B who require immunosuppressive therapy. Nat Rev Gastroenterol Hepatol 2013 [Epub ahead of print].en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
hep27120.pdf
Size:
418.1KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.